Quick Answer
Crinetics Pharmaceuticals, Inc. reported Revenue (ASC 606) of $7.70 million for fiscal year 2025.
Crinetics Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $7.70M | +640.7% |
| 2024 | $1.04M | -74.1% |
| 2023 | $4.01M | — |
| 2022 | $0.00 | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $71.0K | -94.0% |
| 2019 | $1.19M | -50.9% |
| 2018 | $2.43M | +18.7% |
| 2017 | $2.04M | +247.2% |
| 2016 | $589.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $143.0K | — | -86.1% |
| June 30, 2025 | $1.03M | +158.4% | +185.6% |
| March 31, 2025 | $361.0K | -43.6% | — |
| September 30, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2024 | $399.0K | -59.6% | -37.7% |
| March 31, 2024 | $640.0K | -76.1% | +85.0% |
| September 30, 2023 | $346.0K | -24.5% | -65.0% |
| June 30, 2023 | $988.0K | +125.1% | -63.1% |
- Crinetics Pharmaceuticals, Inc. showed an increase of +640.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Crinetics Pharmaceuticals, Inc.’s revenue (asc 606) has grown by 1206.6% (from $589.0 thousand to $7.70 million).
- The most recent figure is from Crinetics Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: